Norcliffe Capital Limited investment portfolio

Aureum Diagnostics develops ultra‑high‑performance, low‑cost electrochemical biosensing platforms that combine a handheld, connected instrument with disposable test strips for rapid, sensitive measurement of metabolites, proteins and nucleic acids. The company targets the point‑of‑care medical diagnostics and biosafety testing markets.

Glen Clova Scientific develops and manufactures virus‑like particle therapeutic vaccines that enable patients to generate their own antibodies, offering a lower‑cost alternative to monoclonal‑antibody biologics for chronic inflammatory, autoimmune and other chronic diseases, and targeting patients who lack access to conventional biologic therapies.